Market Research Store

Asia Pacific Rheumatoid Arthritis Therapeutics Market 2015 Is Expected to Reach $6.9 Billion by 2021 According to Market Research Store

Market Research Store has uploaded latest Report on "Rheumatoid Arthritis Therapeutics in Asia Pacific Markets to 2021" in their database, At Market Research Store, we have market research reports from competent publishers.


Deerfield Beach, FL -- (SBWIRE) -- 08/20/2015 -- Rheumatoid Arthritis Therapeutics in Asia Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Modest Growth Despite Brand Erosion of Blockbuster Anti-TNFs

'Rheumatoid Arthritis Therapeutics in Asia Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Growth In Spite of Brand Erosion of Blockbuster Anti-TNFs, which provides in-depth analysis of Rheumatoid Arthritis (RA) market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2014, along with market forecast until 2021. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

Request For Sample Report Here:

The value of the RA market in the APAC region amounted to an estimated $5.6 billion in 2014 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.3% to reach $6.9 billion by 2021. The key drivers for growth in the APAC market include: the increasing prevalent population and the anticipated market launch of promising pipeline candidates.

The late-stage pipeline which has a potential to stimulate growth during the forecast period include interleukin (IL)-6 inhibitors Sanofi/Regeneron's sarilumab, Johnson & Johnson/GlaxoSmithKline's [J&J/GSK's] sirukumab, small molecules (four janus kinase [JAK] inhibitors: Eli Lilly/Incyte's baricitinib, Loss of patent exclusitivity of major second-line biologic anti-TNF during such as Enbrel, Remicade and Humira by the end of the forecast period is the major barrier for growth in the RA market size in the APAC markets. Preference for less expensive alternatives to branded medicines, such as biosimilars and other alternate therapies is another major barrier in cost-conscious APAC markets, India and China.


The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for RA. It covers and includes:

A brief introduction to RA, including the disease's pathophysiology, risk factors, diagnosis and an overview of pharmacotherapy and treatment algorithms.

In-depth analysis of the drug combinations used in the treatment of RA, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy

A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration

Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action

Multi-scenario forecast market data to 2021, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets

Discussion of the drivers and barriers for market growth

In-depth analysis of licensing and co-development deals involving drugs indicated in RA, including an outline of the key deals

Do Inquiry Before Purchasing Report Here:

Visit Complete Report's Table of Content Here:

Reasons To Buy

Primarily, the report will allow clients to gain a strong understanding of RA, helping to identify and clarify market opportunities and the competitive environment. It will also allow you to:

Understand the RA pipeline and the key trends in the current product development landscape

Observe detailed profiles for the promising pipeline products, including revenue forecasts, and gain an insight into how they are likely to compete in the market, and what their main competitors will be

Follow the trends in RA clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs for RA therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates

Observe the potential growth patterns expected for the RA market over the forecast period, and identify which countries are expected to make the biggest contribution to this growth.

Related News on "Rheumatoid Arthritis Treatment Market" by publisher

Asia-Pacific Rheumatoid Arthritis Treatment Market Value Will Reach $7 Billion by 2021

The Rheumatoid Arthritis (RA) therapeutics market in the Asia-Pacific (APAC) region will expand in value from $5.6 billion in 2014 to an estimated $7 billion by 2021, at a moderate Compound Annual Growth Rate (CAGR) of 3.3%, according to business intelligence provider Research.

The company's latest report* states that of the four major APAC countries, namely Australia, China, India and Japan, the latter will retain the largest share, with its market value expanding from approximately $4.1 billion in 2014 to $4.7 billion by 2021.

Sumith Ladda, says the entry of new therapies over the forecast period will stimulate market growth, with promising pipeline candidates including Eli Lilly and Incyte's baricitinib, Johnson & Johnson and GlaxoSmithKline's sirukumab, and Sanofi and Regeneron's sarilumab.

Ladda says: "Generic first-line drugs, such as Methotrexate, and symptomatic drugs will remain the mainstay of treatment for mild-to-severe RA, and thus their market share is not likely to be vastly affected.

"Second-line therapies, many of which are currently premium drugs and contribute substantially to the annual cost of therapy per patient, will play a greater role in shaping the overall market by 2021. Given the crowded arena, emerging second-line drugs are likely to establish themselves gradually."

The analyst adds that the treatment population is set to grow in the four APAC territories, despite a small decline in the prevalence population in Japan, which will witness the slowest increase at a CAGR of 2.1%.

Ladda continues: "In Japan and Australia, several second-line anti-tumor necrosis factor therapies, such as Remicade, Enbrel and Humira, are due to lose patent protection during the forecast period. Over time, these drugs are likely to experience substantial revenue losses following the approval of biosimilars.

"Indeed, cheaper biosimilars with equivalent efficacy and safety profiles are expected to gain market share by 2021, which is likely to limit overall growth."

Despite this, Research concludes that moderate growth is expected across all four markets between 2014 and 2021. India will lead with a CAGR of 7.7%, followed by China with 4.9% and Australia with 4.5%.